SEC For	m 4 FORN	4) STA	TES	S SE		ITIE	ES AND	EX	CHAI	NGE C	оммі	SSION					
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL					
Section 16. Form 4 or Form 5 obligations may continue. See						A pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person [*] THOMAS TOM C						2. Issuer Name and Ticker or Trading Symbol Vincerx Pharma, Inc. [VINC]								Relationship o eck all applio Directo	able) r	g Pers	vner		
(Last) (First) (Middle) 260 SHERIDAN AVENUE, SUITE 400						3. Date of Earliest Transaction (Month/Day/Year) 05/23/2024									X Officer (give title below) below) See Remarks				
(Street) PALO ALTO CA			94306		4.1								 Filing (Check Applicable Reporting Person re than One Reporting 						
(City)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													l to				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D					action	action 2A. Deeme Execution			, Transaction Dispose Code (Instr. 5)		4. Securit Disposed	of, or Benefic rities Acquired (A) o d Of (D) (Instr. 3, 4		5. Amour Securitie Beneficia	nt of 6. C s For ally (D)		: Direct Indirect	7. Nature of Indirect Beneficial	
					ar) 8) Code V				v 4	Amount	unt (A) or P		Owned F Reported Transact (Instr. 3 a	on(s)			Ownership (Instr. 4)		
		-	Table II - I (uired, Dis s, options					Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$7.38	05/23/2024 ⁽¹⁾			Α		31,250		(2)	03/0	06/2034	Common Stock	31,250	\$0.00	125,00)0	D		
Explanatio	n of Respo	ises:																	

1. The option grant was approved on March 7, 2024, subject to stockholder approval of an amendment to the Vincerx Pharma, Inc. 2020 Stock Incentive Plan. The stockholders approved the amendment on May 23, 2024.

2. One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter.

Remarks:

General Counsel and Chief Legal Officer

By: /s/ Tom C. Thomas

05/29/2024 Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.